ZA907266B - Recombinant aprotinin variants-genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof - Google Patents

Recombinant aprotinin variants-genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof

Info

Publication number
ZA907266B
ZA907266B ZA907266A ZA907266A ZA907266B ZA 907266 B ZA907266 B ZA 907266B ZA 907266 A ZA907266 A ZA 907266A ZA 907266 A ZA907266 A ZA 907266A ZA 907266 B ZA907266 B ZA 907266B
Authority
ZA
South Africa
Prior art keywords
aprotinin variants
variants
genetically engineered
therapeutic use
recombinant
Prior art date
Application number
ZA907266A
Other languages
English (en)
Inventor
Juergen Ebbers
Ebbers Juergen
Dietrich Hoerlein
Hoerlein Dietrich
Michael Schedel
Schedel Michael
Rathindra Das
Das Rathindra
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA907266B publication Critical patent/ZA907266B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA907266A 1989-09-13 1990-09-12 Recombinant aprotinin variants-genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof ZA907266B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3930522A DE3930522A1 (de) 1989-09-13 1989-09-13 Rekombinante aprotinin-varianten - gentechnisches verfahren zur mikrobiellen herstellung von homogen prozessierten aprotinin-varianten sowie die therapeutische anwendung derselben

Publications (1)

Publication Number Publication Date
ZA907266B true ZA907266B (en) 1991-07-31

Family

ID=6389306

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA907266A ZA907266B (en) 1989-09-13 1990-09-12 Recombinant aprotinin variants-genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof

Country Status (15)

Country Link
US (1) US5164482A (da)
EP (1) EP0419878B1 (da)
JP (1) JP2916228B2 (da)
KR (1) KR0169976B1 (da)
AT (1) ATE113074T1 (da)
AU (1) AU632361B2 (da)
CA (1) CA2025070C (da)
DD (1) DD299311A5 (da)
DE (2) DE3930522A1 (da)
DK (1) DK0419878T3 (da)
ES (1) ES2062235T3 (da)
FI (1) FI104724B (da)
HU (1) HU213582B (da)
IL (1) IL95618A (da)
ZA (1) ZA907266B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DK450187D0 (da) * 1987-08-28 1987-08-28 Novo Industri As Fremgangsmaade til fremstilling af proteiner
US5056341A (en) * 1989-06-08 1991-10-15 Sanyo Electric Co., Ltd. Washing machine
US5231010A (en) * 1989-09-13 1993-07-27 Bayer Aktiengesellschaft Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
IL99585A0 (en) * 1990-10-01 1992-08-18 Novo Nordisk As Aprotinin analogues,their production and pharmaceutical compositions containing them
DE4417353A1 (de) * 1994-05-18 1996-01-25 Bayer Ag Verfahren zur Herstellung von rekombinantem Aprotinin und rekombinanten Aprotinin Varianten mit der natürlichen N-terminlaen Sequenz
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
DE19629982A1 (de) 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
DE19725014A1 (de) * 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
WO2003033009A2 (en) * 2001-07-10 2003-04-24 Omnio Ab Novel drug targets for arthritis
US20060218667A1 (en) * 2004-10-12 2006-09-28 Vojdani Fakhrieh S Plant-produced recombinant aprotinin and aprotinin variants
CA2619657C (en) 2005-09-16 2016-01-26 Bayer Cropscience Sa Transplastomic plants expressing lumen-targeted protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037806A (en) * 1985-02-22 1991-08-06 Monsanto Company Biologically active method using somatotropins
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid
DK450187D0 (da) * 1987-08-28 1987-08-28 Novo Industri As Fremgangsmaade til fremstilling af proteiner

Also Published As

Publication number Publication date
HU213582B (en) 1997-08-28
EP0419878A1 (de) 1991-04-03
IL95618A0 (en) 1991-06-30
FI104724B (fi) 2000-03-31
IL95618A (en) 1996-09-12
CA2025070C (en) 2001-01-02
JPH03197496A (ja) 1991-08-28
US5164482A (en) 1992-11-17
EP0419878B1 (de) 1994-10-19
AU632361B2 (en) 1992-12-24
AU6245390A (en) 1991-03-21
KR0169976B1 (ko) 1999-02-01
FI904474A0 (fi) 1990-09-11
DK0419878T3 (da) 1994-11-21
JP2916228B2 (ja) 1999-07-05
ES2062235T3 (es) 1994-12-16
DE59007498D1 (de) 1994-11-24
HUT62031A (en) 1993-03-29
CA2025070A1 (en) 1991-03-14
KR910006483A (ko) 1991-04-29
ATE113074T1 (de) 1994-11-15
HU905877D0 (en) 1991-03-28
DE3930522A1 (de) 1991-03-21
DD299311A5 (de) 1992-04-09

Similar Documents

Publication Publication Date Title
ZA907266B (en) Recombinant aprotinin variants-genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
EP0662827A4 (en) THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS BASED ON NOTCH PROTEINS AND NUCLEIC ACIDS.
NZ228130A (en) Therapeutic composition comprising fenofibrate and a solid surfactant which has been co-micronised; preparatory process
HUT54303A (en) Process for producing medicaments comprising cytokin, suitable for systemic treatment of preneoplastic lesions
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
EP1254956A3 (en) Novel osteoinductive compositions
BG101028A (en) Synthetic peptide analogs of lung surfactant protein sp-c
PH23248A (en) Process for the preparation of quinolone-carboxylic acid
IL72985A0 (en) Homogenous immune interferon fragment,its manufacture and pharmaceutical compositions containing it
HUT62916A (en) Process for producing immunogenic peptides and pharmaceutical compositions comprising same
IL72630A (en) Growth hormone-releasing peptides,their preparation and pharmaceutical preparations therefrom
DE3777845D1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
NZ508816A (en) Bactericidal/permeability-increasing protein (BPI) deletion analogs
HUT47148A (en) Process for producing homogenous recombinant immune interferon fragments and pharmaceutical compositions comprising them
HU9603489D0 (en) Medical composition and process for producing it
ZA894945B (en) Strontium salt,process for the preparation thereof and pharmaceutical compositions containing it
PL316941A1 (en) Variant ofgp 350/220 being not susceptible to composition
CA2002833A1 (en) Interferon-gamma binding proteins
HUT76835A (en) Process for producing pharmaceuticals for treatment of anxiety and panic and gabapentin binding protein
AU3004192A (en) Stabilized pharmaceutical composition of non-glycosylated recombinant human IL2 in reduced form and its preparation process
GR3031254T3 (en) Novel derivatives of peptides therapeutically active in the cascade sequence for blood coagulation, process for their preparation and pharmaceutical compositions containing same
AU3117093A (en) New peptide and pseudopeptide compounds which are therapeutically active in the blood coagulation cascade, process for preparing them and pharmaceutical compositions containing them
ZA917700B (en) Peptide and pseudopeptide compounds that are therapeutically active in the blood coagulation cascade,process for the preparation thereof,and pharmaceutical compositions containing them
EP0342015A3 (en) Peptides, their use and pharmaceutical compositions containing them